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Uncertain Identity of
Doxorubicin-Resistant MCF-7
Cell Lines Expressing
Mutated p53
The doxorubicin (ADR)-selected hu-
man breast cancer cell line (MCF-7/
ADR-RES) has been a useful model for
a multidrug-resistant subline in cancer
research. However, a recent letter to the
Journal has alerted the scientific com-
munity about the finding that MCF-7/
ADR-RES is not a MCF-7-derived cell
line. This report led to a change of no-
menclature from MCF-7/ADR-RES to
NCI/ADR-RES (1).
Another cell line (MCF-7 TH) has
been independently selected by doxoru-
bicin treatment at the National Cancer
Institute (NCI) and demonstrated some
of the same, interesting characteristics
of NCI/ADR-RES, such as high levels
of MDR-1 and P-glycoprotein expres-
sion and a mutated p53 tumor suppres-
sor protein (2). Of interest, both cell
lines exhibit the same 21-base-pair de-
letion beginning at exon 5 spanning
codons 126–133 (3). We used this cell
line to analyze the effect of the multi-
drug-resistant phenotype and p53 on the
efficacy of anticancer drugs with differ-
ent mechanisms of action. Various anti-
cancer drugs were more effective in the
MCF-7 TH subline than in the parental
MCF-7 line, despite a dysfunctional p53
and multidrug-resistant phenotype.
These agents induced apoptosis in
MCF-7 TH cells as demonstrated by the
characteristic morphologic features. Be-
cause the activity of specific caspases
might affect the propensity of a cell to
undergo apoptosis, we examined expres-
sion level and cleavage pattern of differ-
ent caspases in drug-treated MCF-7 TH
and parental cells. The MCF-7 TH cell
line strongly expressed caspase-3 (Fig.
1, A) and cisplatin treatment led to a
significant increase of caspase-3-like ac-
tivity as measured by use of the fluoro-
genic caspase-3-specific substrate Asp-
Glu-Val-Asp-7-amino-4-trifluoromethyl
coumarin (DEVD-afc) (Fig. 1, B). The
MCF-7 cell line has lost caspase-3 be-
cause of a 47-base-pair deletion within
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exon 3 of the CASP-3 gene (4). These
findings thus suggest that MCF-7 TH
also is not derived from MCF-7. This
hypothesis was confirmed by DNA fin-
gerprinting, which demonstrated that pa-
rental MCF-7 and MCF-7 TH cannot
have the same donor, because they differ
in all loci except the sex chromosome
locus. The analyses were repeated with
several different batches of parental
MCF-7 and TH cells. Furthermore,
MCF-7 parental cells from different
sources were compared and all showed
an identical allelic distribution profile of
the short tandem repeat loci by DNA
fingerprinting. The only cell line show-
ing identity with MCF-7 TH by DNA
fingerprinting was NCI/ADR-RES.
Thus, MCF-7 TH, like NCI/ADR-RES,
is not a MCF-7-related cell line.
This finding is important because
doxorubicin-resistant cell lines are a
popular tool for new drug development.
In a recent article in the Journal, Leoni
et al. (5) used NCI/ADR-RES to inves-
tigate a novel microtubule-binding inda-
none. Despite the fact that these authors
mislabeled the cell line MCF-7/ADR-
RES (1), they did not realize that their
observation of caspase-3 activation by
the drug would not have been possible
in a MCF-7-derived cell line, which
contains no caspase-3 (4) (Fig. 1, A).
The use of a mislabeled cell line can
clearly introduce a major source of mis-
interpretation and possibly wrong strate-
gic decisions in drug development. We,
thus, strongly suggest that the identity of
cell lines be assessed regularly by DNA
fingerprinting because this is a simple
and reliable method for identity valida-
tion.
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Fig. 1. Analysis of caspase-3 protein expression
and activity in MCF-7 and MCF-7 TH cell lines.
A) Immunoblot analysis of baseline caspase-3 ex-
pression in Jurkat (positive control), MCF-7, and
MCF-7 TH cells using a caspase-3 polyclonal an-
tibody (6). B) Activation of caspase-3 by cisplatin.
MCF-7 TH cells were treated with 10 g/mL cis-
platin. At the indicated time points, caspase-3 ac-
tivity was measured with the specific fluorogenic
subs t r a t e Asp-Glu -Va l -Asp-7 -amino-4 -
trifluoromethyl coumarin (DEVD-afc) (7).
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postlabeling technique in which two cy-
clobutane pyrimidine dimers, T  T
and T C, and two 6-4 photoproducts,
T–T and T–C, were quantified based on
external standards. Many of the findings
challenge results from earlier, published
in vitro assays. Repair kinetics of dimers
and 6-4 photoproducts encompassed fast
and slow components, probably relating
to repair of transcribed and nontran-
scribed sequences, respectively (3).
Dimers were removed considerably
more slowly than 6-4 photoproducts,
with 50% removal times of approxi-
mately 15 and 5 hours, respectively;
dimers at TT sites were repaired slower
than those at TC sites (3). A 20-fold in-
terindividual variation in repair rates
was observed. Because we have applied
this test to relatively small numbers of
case subjects and matched control sub-
jects, we need to refrain from making
general conclusions. However, age does
not cause a decline in repair of UVR
damage in situ, in contrast to results
from the host-mediated assay (4). As
evidence of further contradictions, basal
cell carcinoma patients have not dis-
played lower rates of DNA repair (5),
and melanoma patients appear to repair
DNA damage like healthy matched
control subjects (6). The most recent de-
velopment is a postlabeling assay for ex-
creted urinary photoproducts, informa-
tive of the total-body UV damage (7).
Valid DNA repair tests will also be
exceedingly valuable to analyze the
functional effects of DNA repair gene
polymorphisms, which is currently a
popular research area. Here we concur
with Berwick and Vineis who state, in
reference to the bewildering literature
on attempts to match metabolic geno-
types to risk of any cancers: “It is not
clear that conducting these studies with-
out concomitant studies of expression
and/or function will be fruitful.” Con-
ducting DNA repair tests in the relevant
human organs will be fruitful and rel-
evant.
KARI HEMMINKI
GUOGANG XU
FRANK LE CURIEUX
REFERENCES
(1) Berwick M, Vineis P. Markers of DNA repair
and susceptibility to cancer in humans: an epi-
demiologic review. J Natl Cancer Inst 2000;
92:874–97.
(2) Bykov VJ, Jansen CT, Hemminki K. High lev-
els of dipyrimidine dimers are induced in hu-
man skin by solar-simulating UV radiation.
Cancer Epidemiol Biomarkers Prev 1998;7:
199–202.
(3) Bykov VJ, Sheehan JM, Hemminki K, Young
AR. In situ repair of cyclobutane pyrimidine
dimers and 6-4 photoproducts in human skin
exposed to solar simulating radiation. J Invest
Dermatol 1999;112:326–31.
(4) Xu G, Snellman E, Bykov VJ, Jansen CT,
Hemminki K. Effect of age on the formation
and repair of UV photoproducts in human skin
in situ. Mutat Res 2000;459:195–202.
(5) Xu G, Snellman E, Jansen CT, Hemminki K.
Levels and repair of cyclobutane pyrimidine
dimers and 6-4 photoproducts in skin of spo-
radic basal cell carcinoma patients. J Invest
Dermatol 2000;115:95–9.
(6) Xu G, Snellman E, Bykov VJ, Jansen CT,
Hemminki K. Cutaneous malignant melanoma
patients have normal repair kinetics of ultra-
violet-induced DNA damage in skin in situ. J
Invest Dermatol 2000;114:628–31.
(7) Hemminki K, Xu G, Le Curieux F. Ultraviolet
radiation-induced photoproducts in human
skin DNA as biomarkers of damage and its
repair. IARC Sci Publ. No. 154. In press 2000.
NOTES
Affiliation of authors: Department of Biosci-
ences at Novum, Karolinska Institute, Huddinge,
Sweden.
Correspondence to: Kari Hemminki, M.D.,
Ph.D., Karolinska Institute, Department of Biosci-
ences at Novum, 141 57 Huddinge, Sweden.
RESPONSE
We are pleased that Hemminki et al.
have taken seriously the challenge in our
recent review (1) to develop definitive
molecular assays for DNA repair. Their
conclusions echo ours: neither they nor
we really know what the studies in lym-
phocytes measure. Clearly, their re-
search publications in 1999 and 2000
will be valuable in developing the tech-
niques for studying DNA repair.
We find it interesting that the two
studies using kinetic tests on skin biop-
sies, which Hemminki et al. believe ful-
fill the criterion of biologic relevance,
had positive and statistically significant
results (although carried out in only a
few subjects). Roth et al. (2) showed that
melanoma subjects had lower DNA re-
pair rates than control subjects (P <
.001), and Alcalay et al. (3) showed that
dimers in basal cell carcinoma subjects
were eliminated less rapidly than in con-
trol subjects (P < .05).
The overall message that we derive
from our analysis of the literature is that
a considerable number of studies consis-
tently found an association between bio-
logic tests, whose significance is still
obscure, and cancer at several sites.
Looking at it this way, we agree with
Hemminki and colleagues that further
clarification of the biologic background
is crucial. However, at this time, we
think that focusing our attention on the
design of the studies, reproducibility,
sample size, and selection of control
subjects was necessary to draw valid
conclusions at the population level. The
issue of biologic relevance of studies of
DNA repair in lymphocytes is critical
for epidemiologic studies where asso-
ciations are derived from numerous sub-
jects to define small reproducible alter-
ations that may be important. Most of
the work Hemminki et al. cite has been
conducted in very small groups and has
not yet been reproduced.
In sum, the issues raised by Hem-
minki et al. are critical for the appropri-
ate assessment of DNA repair. We hope
that other eminent scientists will join
their efforts to develop appropriate as-
says for DNA repair.
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